Overview

Update
Acquisitions
1 Acquisition
IPO / Stock
Went Public on Nov 23, 2010 / NASDAQ:ZGNX
Headquarters:
San Diego, CA
Description:
Zogenix engages in the development and commercialization of products for the treatment of central nervous system disorders and pain.
Founders:
,
Categories:
Pharmaceutical, Health Care, Biotechnology
Website:
http://www.zogenix.com
Social:

Company Details

Update

At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products.

We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Funding Rounds (6) - $167.06M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jul, 2010$15M / Venture6
Dec, 2009$35M / Series B1
Oct, 2009$35.96M / Series B5
May, 2009$3.1M / Debt Financing0
Jan, 2008$18M / Series B4
Aug, 2006$60M / Series A5

Acquisitions (1)

Update
DateAcquiredAmount
Oct 27, 2014$35M in Cash & Stock

Current Team (7)

Update

Offices/Locations (1)

Update
  • Headquarters

    12671 High Bluff Dr

    San Diego, CA 92130

    USA

Past Team (1)

Update

Images (1)

Update

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos